

**REQUEST FOR AUTHORISATION OF A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES AND FOR OPINION OF THE ETHICS COMMITTEES IN THE COMMUNITY**

*For official use:*

Date of receiving the request :  Date of request for information to make it valid :	Date of request for additional information :	Grounds for non acceptance/ negative opinion : <input type="checkbox"/>  Give date :
Date of valid application :  Date of start of procedure :	Date of receipt of additional / amended information :	Authorisation/ positive opinion : <input type="checkbox"/>  Give date:
Competent authority registration number :  Ethics Committee registration number :		Withdrawal of application : <input type="checkbox"/>  Give date :

*To be filled in by the applicant:*

The questions in this form for the request for authorisation from the Competent Authority are also relevant for the opinion from an Ethics Committee (it represents module 1 of the form for applying to an ethics committee) and can be used as part of that application. Please indicate the relevant purpose in a box below.

**REQUEST FOR AUTHORISATION TO THE COMPETENT AUTHORITY: ✓**

**A. TRIAL IDENTIFICATION**

**A.1 Member State in which the submission is being made : UNITED KINGDOM**

A.2 EudraCT number<sup>1</sup>: **2007-006749-42**

A.3 Full title of the trial:

**Safety and tolerability of clopidogrel when added to aspirin and dipyridamole in high risk patients with recent ischaemic stroke: a randomised controlled trial**

A.4 Sponsor's protocol code number<sup>2</sup>: **31350**

Sponsor's protocol version<sup>2</sup>: **1.0**

Sponsor's protocol date<sup>2</sup>: **2008-07-24**

A.5 Name or abbreviated title of the trial where available:

**TARDIS**

A.6 ISRCTN number<sup>3</sup>, if available :

A.7 Is this a resubmission ?    yes  no

If Yes, indicate the resubmission letter<sup>4</sup>: **First submission**

---

<sup>1</sup> Append the EudraCT number confirmation receipt

<sup>2</sup> Any translation of the protocol should be assigned the same date and version as those in the original document.

<sup>3</sup> International Standard Randomised Controlled Trial Number. Sponsors may wish to use an International Standard Randomised Controlled Trial Number (ISRCTN) to identify their trial in addition to the EudraCT number; for instance if their trial is part of a multinational trial with sites outside the Community. They can obtain the number and guidance from the Current Controlled Trials website <http://www.controlled-trials.com/isrctn> to which there is a link from the EudraCT database website <http://www.eudract.emea.europa.eu>. When available they should provide it in Section A.6 of the application form.

<sup>4</sup> For a resubmission following previous withdrawal of an application or unfavourable opinion of an ethics committee, or previous withdrawal of an application or refusal of a request by the competent authority, enter a letter in the sequence, A for first resubmission, B for second, C for third et seq.

**B. IDENTIFICATION OF THE SPONSOR RESPONSIBLE FOR THE REQUEST**

<b>B.1 Sponsor</b>	
B.1.1 Name of organisation :	University of Nottingham
B.1.2 Name of the person to contact:	Paul Cartledge
B.1.3 Address :	Kings Meadow Campus, Lenton Lane Nottingham NG7 2NR UNITED KINGDOM
B.1.4 Telephone number :	01159515679
B.1.5 Fax number :	01159513633
B.1.6 e-mail:	paul.cartledge@nottingham.ac.uk
B.3 Status of the sponsor :	B.3.1 commercial <sup>6</sup> <input type="checkbox"/> B.3.2 non commercial <input checked="" type="checkbox"/>

<b>B.2 Legal representative<sup>5</sup> of the sponsor in the Community for the purpose of this trial (if different from the sponsor)</b>
B.2.1 Name of organisation :
B.2.2 Name of the person to contact:
B.2.3 Address :
B.2.4 Telephone number :
B.2.5 Fax number :
B.2.6 e-mail:

<sup>5</sup> : In accordance with article 19 of Directive 2001/20/EC

<sup>6</sup> : A commercial sponsor is a person or organisation that takes responsibility for a trial which at the time of the application is part of the development programme for a marketing authorisation of a medicinal product.

**C. APPLICANT IDENTIFICATION, (please tick the appropriate box)**

<b>C.1 Request for the competent authority ✓</b>	
C.1.1 - Sponsor	<input type="checkbox"/>
C.1.2 - Legal representative of the sponsor	<input type="checkbox"/>
C.1.3 - Person or organisation authorised by the sponsor to make the application.	<input checked="" type="checkbox"/>
C.1.4 Complete the details of the applicant below even if they are provided elsewhere on the form:	
C.1.4.1 Organisation :	University of Nottingham
C.1.4.2 Name of contact person :	Philip Bath
C.1.4.3 Address :	Clinical Sciences Building, City Hospital, Hucknall Road Nottingham NG5 1PB
C.1.4.4 Telephone number :	0115 8231765
C.1.4.5 Fax number :	0115 8237167
C.1.4.6 e-mail:	timothy.england@nottingham.ac.uk
C.1.5 Request to receive an .xml copy of CTA data :	
C.1.5.1 Do you want an .xml file copy of the CTA form data saved on EudraCT ?	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
C.1.5.1.1 If Yes provide the e-mail address(es) to which it should be sent (up to 5 addresses) :	
C.1.5.1.2 Do you want to receive this via password protected link(s) <sup>7</sup> ?	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
If you answer No to question C.1.5.1.2 the .xml file will be transmitted by less secure e-mail link(s)	

<sup>7</sup> This requires a EudraLink account. (See [www.eudract.emea.europa.eu](http://www.eudract.emea.europa.eu)) for details)

## D. INFORMATION ON EACH IMP

Information on each 'bulk product' before trial-specific operations (blinding, trial specific packaging and labelling) should be provided in this section for each investigational medicinal product (IMP) being tested including each comparator and each placebo, if applicable. If the trial is performed with several products use extra pages and give each product a sequential number in D.1.1. If the product is a combination product information should be given for each active substance.

### D.1 IMP IDENTIFICATION

Indicate which of the following is described below, then repeat as necessary for each of the numbered IMPs to be used in the trial(assign numbers from 1-n):

- D.1.1 This refers to the IMP number :** PR1
- D.1.2 IMP being tested** ✓
- D.1.3 IMP used as a comparator**

*for placebo go directly to D.7*

**D.2 STATUS OF THE IMP.** If the IMP has a marketing authorisation in the Member State concerned by this application but the trade name and marketing authorisation holder are not fixed in the protocol, go to section D.2.2.

- D.2.1 Has the IMP to be used in the trial a marketing authorisation ?      yes  no
- D.2.1.1 If yes to D.2.1, specify for the product to be used in the trial :
- D.2.1.1.1 Trade name<sup>9</sup>
- D.2.1.1.2 Name of the MA holder<sup>9</sup>
- D.2.1.1.3 MA number (if MA granted by a Member State)<sup>9</sup>
- D.2.1.1.4 Is the IMP modified in relation to its MA ?      yes  no
- D.2.1.1.4.1 If Yes, please specify
- D.2.1.2 Which country granted the MA ?
- D.2.1.2.1 Is this the Member State concerned with this application ?      yes  no
- D.2.1.2.2 Is this another Member State ?      yes  no

**D.2.2 Situations where an IMP to be used in the CT has a MA in the MS concerned , but the protocol allows that any brand of the IMP with a MA in that MS be administered to the trial subjects and it is not possible to clearly identify the IMP(s) in advance of the trial start**

D.2.2.1 In the protocol, is treatment defined only by active substance ?	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
D.2.2.1.1 If Yes, give active substance in D.3.8 or D.3.9	
D.2.2.2 In the protocol, do treatment regimens allow different combinations of marketed products used according to local clinical practice at some or all investigator sites in the MS ?	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
D.2.2.2.1 If Yes, give active substance in D.3.8 or D.3.9	
D.2.2.3 The products to be administered as IMPs are defined as belonging to an ATC group <sup>9</sup> .	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
D.2.2.3.1 If Yes, give the ATC group of the applicable authorised codes in the ATC code field (level 3 or the level that can be defined) in D.3.3	
D.2.2.4 Other :	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
D.2.2.4.1 If Yes, please specify :	

**D.2.3 IMPD submitted :**

D.2.3.1 Full IMPD	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
D.2.3.2 Simplified IMPD <sup>10</sup> .	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
D.2.3.3 Summary of product characteristics (SmPC) only	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>

**D.2.4 Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community ?**

yes  no

D.2.4.1 If Yes, specify which Member States :  
UNITED KINGDOM

**D.2.5 Has the IMP been designated in this indication as an orphan drug in the Community ?**

yes  no

D.2.5.1 If yes, give the orphan drug designation number<sup>11</sup>:

**D.2.6 Has the IMP been the subject of scientific advice related to this clinical trial ?**

yes  no

D.2.6.1 If Yes to D.2.6 please indicate source of advice and provide a copy in the CTA request :

D.2.6.1.1 From the CHMP <sup>12</sup>?

yes  no

D.2.6.1.2 From a MS competent authority ?

yes  no

<sup>9</sup> Available from the Summary of Product Characteristics

<sup>10</sup> Provide justification for using simplified dossier in the covering letter.

<sup>11</sup> According to the Community register on orphan medicinal products (Regulation (EC) n° 141/2000) :  
<http://pharmacos.eudra.org/F2/register/orphreg.htm>

<sup>12</sup> Committee for Medicinal Products for Human Use of the European Medicines Agency.

### D.3 DESCRIPTION OF THE IMP

**D.3.1 Product name where applicable<sup>13</sup> :** Aspirin

**D.3.2 Product code where applicable<sup>14</sup> :**

**D.3.3 ATC code, if officially registered<sup>15</sup> :** B01AC06

**D.3.4 Pharmaceutical form (use standard terms) :** Tablet

**D.3.5 Maximum duration of treatment of a subject according to the protocol :**

90 days (then would continue as normal treatment for stroke)

**D.3.6 Maximum dose allowed (specify : per day or total dose; units and route of administration) :**

300mg loading dose then 75mg daily

Per day or total dose : Per day

Units : 75mg mg milligram(s)

Route of administration : Enteral Use

**D.3.7 Route of administration (use standard terms):** Enteral Use

Oral Use

---

**D.3.8 Name of each active substance (INN or proposed INN if available) :** Aspirin

**D.3.9 Other available name for each active substance (CAS<sup>16</sup>, current sponsor code(s), other descriptive name, etc : provide all available) :**

- CAS 50782

- Current sponsor code(s)


- Other Descriptive name ACETYLSALICYLIC ACID

**D.3.10 Strength (specify all strengths to be used) :**

D.3.10.1 - concentration unit : mg milligram(s)

D.3.10.2 - concentration type (“exact number”, “range”, “more than” or “up to”). range

D.3.10.3 - concentration number : 25 300



<sup>13</sup> To be provided only where there is no tradename. This is the name routinely used by the sponsor to identify the IMP in the CT documentation (protocol, IB...)

<sup>14</sup> To be provided only where there is no tradename. This is the code designated by the sponsor which represents the name routinely used by the sponsor to identify the product in the CT documentation. For example, a code may be used for combinations of drugs or drugs and devices..

<sup>15</sup> Available from the Summary of Product Characteristics

<sup>16</sup> Chemical Abstracts Service.



**D.4. BIOLOGICAL / BIOTECHNOLOGICAL INVESTIGATIONAL MEDICINAL PRODUCTS INCLUDING VACCINES**

<b>D.4.1 Type of product</b>	
D.4.1.1 - Extractive	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.2 - Recombinant	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.3 - Vaccine	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.4 - GMO	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.5 - Plasma derived products	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.6 - Others	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.6.1 If others, specify :	

**D.5 SOMATIC CELL THERAPY INVESTIGATIONAL MEDICINAL PRODUCT (NO GENETIC MODIFICATION)**

<b>D.5.1 Origin of cells</b>	
D.5.1.1 - Autologous	yes <input type="checkbox"/> no <input type="checkbox"/>
D.5.1.2 - Allogeneic	yes <input type="checkbox"/> no <input type="checkbox"/>
D.5.1.3 - Xenogeneic	yes <input type="checkbox"/> no <input type="checkbox"/>
D.5.1.3.1 - If yes, specify species of origin :	

**D.5.2 Type of cells**

D.5.2.1 - Stem cells yes  no

D.5.2.2 - Differentiated cells yes  no

D.5.2.2.1 If yes, specify the type (e.g. keratinocytes, fibroblasts, chondrocytes,...) :

D.5.2.3 - Others : yes  no

D.5.2.3.1 If others, specify :

**D.6. GENE THERAPY INVESTIGATIONAL MEDICINAL PRODUCTS**

**D.6.1 Gene(s) of interest :**

**D.6.2 In vivo gene therapy:**

**D.6.3 Ex vivo gene therapy :**

**D.6.4 Type of gene transfer product**

D.6.4.1 - Nucleic acid (e.g. plasmid) : yes  no

If yes, specify

D.6.4.1.1 - Naked : yes  no

D.6.4.1.2 - Complexed : yes  no

D.6.4.2 - Viral vector : yes  no

D.6.4.2.1 If yes, specify the type : adenovirus, retrovirus, AAV, ...:

D.6.4.3 - Others : yes  no

D.6.4.3.1 If others, specify :

**D.6.5 Genetically modified cells :**

yes  no

If yes, specify origin of the cells :

D.6.5.1 - Autologous :

yes  no

D.6.5.2 - Allogeneic :

yes  no

D.6.5.3 - Xenogeneic :

yes  no

D.6.5.3.1 - If yes, specify species of origin :

D.6.5.4 - Other type of cells (hematopoietic stem cells, ...): yes  no

-If Yes specify :

**D.6.6 Comments on novel aspects of gene therapy investigational product if any (free text) :**

## D.1 IMP IDENTIFICATION

Indicate which of the following is described below, then repeat as necessary for each of the numbered IMPs to be used in the trial(assign numbers from 1-n):

- D.1.1 This refers to the IMP number :** PR2
- D.1.2 IMP being tested** ✓
- D.1.3 IMP used as a comparator**

*for placebo go directly to D.7*

**D.2 STATUS OF THE IMP.** If the IMP has a marketing authorisation in the Member State concerned by this application but the trade name and marketing authorisation holder are not fixed in the protocol, go to section D.2.2.

- D.2.1 Has the IMP to be used in the trial a marketing authorisation ?      yes  no
- D.2.1.1 If yes to D.2.1, specify for the product to be used in the trial :
- D.2.1.1.1 Trade name<sup>9</sup>
- D.2.1.1.2 Name of the MA holder<sup>9</sup>
- D.2.1.1.3 MA number (if MA granted by a Member State)<sup>9</sup>
- D.2.1.1.4 Is the IMP modified in relation to its MA ?      yes  no
- D.2.1.1.4.1 If Yes, please specify
- D.2.1.2 Which country granted the MA ?
- D.2.1.2.1 Is this the Member State concerned with this application ?      yes  no
- D.2.1.2.2 Is this another Member State ?      yes  no

**D.2.2 Situations where an IMP to be used in the CT has a MA in the MS concerned , but the protocol allows that any brand of the IMP with a MA in that MS be administered to the trial subjects and it is not possible to clearly identify the IMP(s) in advance of the trial start**

D.2.2.1 In the protocol, is treatment defined only by active substance ?	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
D.2.2.1.1 If Yes, give active substance in D.3.8 or D.3.9	
D.2.2.2 In the protocol, do treatment regimens allow different combinations of marketed products used according to local clinical practice at some or all investigator sites in the MS ?	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
D.2.2.2.1 If Yes, give active substance in D.3.8 or D.3.9	
D.2.2.3 The products to be administered as IMPs are defined as belonging to an ATC group <sup>9</sup> .	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
D.2.2.3.1 If Yes, give the ATC group of the applicable authorised codes in the ATC code field (level 3 or the level that can be defined) in D.3.3	
D.2.2.4 Other :	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
D.2.2.4.1 If Yes, please specify :	

**D.2.3 IMPD submitted :**

D.2.3.1 Full IMPD	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
D.2.3.2 Simplified IMPD <sup>10</sup> .	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
D.2.3.3 Summary of product characteristics (SmPC) only	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>

**D.2.4 Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community ?**

yes  no

D.2.4.1 If Yes, specify which Member States :  
UNITED KINGDOM

**D.2.5 Has the IMP been designated in this indication as an orphan drug in the Community ?**

yes  no

D.2.5.1 If yes, give the orphan drug designation number<sup>11</sup>:

**D.2.6 Has the IMP been the subject of scientific advice related to this clinical trial ?**

yes  no

D.2.6.1 If Yes to D.2.6 please indicate source of advice and provide a copy in the CTA request :

D.2.6.1.1 From the CHMP <sup>12</sup>?

yes  no

D.2.6.1.2 From a MS competent authority ?

yes  no

<sup>9</sup> Available from the Summary of Product Characteristics

<sup>10</sup> Provide justification for using simplified dossier in the covering letter.

<sup>11</sup> According to the Community register on orphan medicinal products (Regulation (EC) n° 141/2000) :  
<http://pharmacos.eudra.org/F2/register/orphreg.htm>

<sup>12</sup> Committee for Medicinal Products for Human Use of the European Medicines Agency.

### D.3 DESCRIPTION OF THE IMP

**D.3.1 Product name where applicable<sup>13</sup> :** Aspirin

**D.3.2 Product code where applicable<sup>14</sup> :**

**D.3.3 ATC code, if officially registered<sup>15</sup> :** B01AC06

**D.3.4 Pharmaceutical form (use standard terms) :** Dispersible Tablet

**D.3.5 Maximum duration of treatment of a subject according to the protocol :**

90 days (then would continue as normal treatment for stroke)

**D.3.6 Maximum dose allowed (specify : per day or total dose; units and route of administration) :**

300mg loading dose then 75mg daily

Per day or total dose : Per day

Units : 75mg mg milligram(s)

Route of administration : Enteral Use

**D.3.7 Route of administration (use standard terms):** Enteral Use

Oral Use

---

**D.3.8 Name of each active substance (INN or proposed INN if available) :** Aspirin

**D.3.9 Other available name for each active substance (CAS<sup>16</sup>, current sponsor code(s), other descriptive name, etc : provide all available) :**

- CAS 50782

- Current sponsor code(s)

- Other Descriptive name ACETYLSALICYLIC ACID

**D.3.10 Strength (specify all strengths to be used) :**

D.3.10.1 - concentration unit : mg milligram(s)

D.3.10.2 - concentration type (“exact number”, “range”, “more than” or “up to”). range

D.3.10.3 - concentration number : 75 300



<sup>13</sup> To be provided only where there is no tradename. This is the name routinely used by the sponsor to identify the IMP in the CT documentation (protocol, IB...)

<sup>14</sup> To be provided only where there is no tradename. This is the code designated by the sponsor which represents the name routinely used by the sponsor to identify the product in the CT documentation. For example, a code may be used for combinations of drugs or drugs and devices..

<sup>15</sup> Available from the Summary of Product Characteristics

<sup>16</sup> Chemical Abstracts Service.



**D.4. BIOLOGICAL / BIOTECHNOLOGICAL INVESTIGATIONAL MEDICINAL PRODUCTS INCLUDING VACCINES**

<b>D.4.1 Type of product</b>	
D.4.1.1 - Extractive	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.2 - Recombinant	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.3 - Vaccine	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.4 - GMO	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.5 - Plasma derived products	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.6 - Others	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.6.1 If others, specify :	

**D.5 SOMATIC CELL THERAPY INVESTIGATIONAL MEDICINAL PRODUCT (NO GENETIC MODIFICATION)**

<b>D.5.1 Origin of cells</b>	
D.5.1.1 - Autologous	yes <input type="checkbox"/> no <input type="checkbox"/>
D.5.1.2 - Allogeneic	yes <input type="checkbox"/> no <input type="checkbox"/>
D.5.1.3 - Xenogeneic	yes <input type="checkbox"/> no <input type="checkbox"/>
D.5.1.3.1 - If yes, specify species of origin :	

**D.5.2 Type of cells**

D.5.2.1 - Stem cells yes  no

D.5.2.2 - Differentiated cells yes  no

D.5.2.2.1 If yes, specify the type (e.g. keratinocytes, fibroblasts, chondrocytes,...) :

D.5.2.3 - Others : yes  no

D.5.2.3.1 If others, specify :

**D.6. GENE THERAPY INVESTIGATIONAL MEDICINAL PRODUCTS**

**D.6.1 Gene(s) of interest :**

**D.6.2 In vivo gene therapy:**

**D.6.3 Ex vivo gene therapy :**

**D.6.4 Type of gene transfer product**

D.6.4.1 - Nucleic acid (e.g. plasmid) : yes  no

If yes, specify

D.6.4.1.1 - Naked : yes  no

D.6.4.1.2 - Complexed : yes  no

D.6.4.2 - Viral vector : yes  no

D.6.4.2.1 If yes, specify the type : adenovirus, retrovirus, AAV, ...:

D.6.4.3 - Others : yes  no

D.6.4.3.1 If others, specify :

**D.6.5 Genetically modified cells :**

yes  no

If yes, specify origin of the cells :

D.6.5.1 - Autologous :

yes  no

D.6.5.2 - Allogeneic :

yes  no

D.6.5.3 - Xenogeneic :

yes  no

D.6.5.3.1 - If yes, specify species of origin :

D.6.5.4 - Other type of cells (hematopoietic stem cells, ...): yes  no

-If Yes specify :

**D.6.6 Comments on novel aspects of gene therapy investigational product if any (free text) :**

## D.1 IMP IDENTIFICATION

Indicate which of the following is described below, then repeat as necessary for each of the numbered IMPs to be used in the trial(assign numbers from 1-n):

- D.1.1 This refers to the IMP number :** PR3
- D.1.2 IMP being tested** ✓
- D.1.3 IMP used as a comparator**

*for placebo go directly to D.7*

**D.2 STATUS OF THE IMP.** If the IMP has a marketing authorisation in the Member State concerned by this application but the trade name and marketing authorisation holder are not fixed in the protocol, go to section D.2.2.

- D.2.1 Has the IMP to be used in the trial a marketing authorisation ?      yes  no
- D.2.1.1 If yes to D.2.1, specify for the product to be used in the trial :
- D.2.1.1.1 Trade name<sup>9</sup>
- D.2.1.1.2 Name of the MA holder<sup>9</sup>
- D.2.1.1.3 MA number (if MA granted by a Member State)<sup>9</sup>
- D.2.1.1.4 Is the IMP modified in relation to its MA ?      yes  no
- D.2.1.1.4.1 If Yes, please specify
- D.2.1.2 Which country granted the MA ?
- D.2.1.2.1 Is this the Member State concerned with this application ?      yes  no
- D.2.1.2.2 Is this another Member State ?      yes  no

**D.2.2 Situations where an IMP to be used in the CT has a MA in the MS concerned , but the protocol allows that any brand of the IMP with a MA in that MS be administered to the trial subjects and it is not possible to clearly identify the IMP(s) in advance of the trial start**

D.2.2.1 In the protocol, is treatment defined only by active substance ?	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
D.2.2.1.1 If Yes, give active substance in D.3.8 or D.3.9	
D.2.2.2 In the protocol, do treatment regimens allow different combinations of marketed products used according to local clinical practice at some or all investigator sites in the MS ?	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
D.2.2.2.1 If Yes, give active substance in D.3.8 or D.3.9	
D.2.2.3 The products to be administered as IMPs are defined as belonging to an ATC group <sup>9</sup> .	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
D.2.2.3.1 If Yes, give the ATC group of the applicable authorised codes in the ATC code field (level 3 or the level that can be defined) in D.3.3	
D.2.2.4 Other :	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
D.2.2.4.1 If Yes, please specify :	

**D.2.3 IMPD submitted :**

D.2.3.1 Full IMPD	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
D.2.3.2 Simplified IMPD <sup>10</sup> .	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
D.2.3.3 Summary of product characteristics (SmPC) only	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>

**D.2.4 Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community ?**

yes  no

D.2.4.1 If Yes, specify which Member States :  
UNITED KINGDOM

**D.2.5 Has the IMP been designated in this indication as an orphan drug in the Community ?**

yes  no

D.2.5.1 If yes, give the orphan drug designation number<sup>11</sup>:

**D.2.6 Has the IMP been the subject of scientific advice related to this clinical trial ?**

yes  no

D.2.6.1 If Yes to D.2.6 please indicate source of advice and provide a copy in the CTA request :

D.2.6.1.1 From the CHMP <sup>12</sup>?

yes  no

D.2.6.1.2 From a MS competent authority ?

yes  no

<sup>9</sup> Available from the Summary of Product Characteristics

<sup>10</sup> Provide justification for using simplified dossier in the covering letter.

<sup>11</sup> According to the Community register on orphan medicinal products (Regulation (EC) n° 141/2000) :  
<http://pharmacos.eudra.org/F2/register/orphreg.htm>

<sup>12</sup> Committee for Medicinal Products for Human Use of the European Medicines Agency.

### D.3 DESCRIPTION OF THE IMP

**D.3.1 Product name where applicable<sup>13</sup> :** Aspirin

**D.3.2 Product code where applicable<sup>14</sup> :**

**D.3.3 ATC code, if officially registered<sup>15</sup> :** B01AC06

**D.3.4 Pharmaceutical form (use standard terms) :** Suppository

**D.3.5 Maximum duration of treatment of a subject according to the protocol :**

90 days (then would continue as normal treatment for stroke)

**D.3.6 Maximum dose allowed (specify : per day or total dose; units and route of administration) :**

300mg loading dose then 75mg daily

Per day or total dose : Per day

Units : 75mg mg milligram(s)

Route of administration : Rectal Use

**D.3.7 Route of administration (use standard terms):** Rectal Use

---

**D.3.8 Name of each active substance (INN or proposed INN if available) :** Aspirin

**D.3.9 Other available name for each active substance (CAS<sup>16</sup>, current sponsor code(s), other descriptive name, etc : provide all available) :**

- CAS 50782

- Current sponsor code(s)

- Other Descriptive name ACETYLSALICYLIC ACID

**D.3.10 Strength (specify all strengths to be used) :**

D.3.10.1 - concentration unit : mg milligram(s)

D.3.10.2 - concentration type (“exact number”, “range”, “more than” or “up to”). range

D.3.10.3 - concentration number : 150 300



<sup>13</sup> To be provided only where there is no tradename. This is the name routinely used by the sponsor to identify the IMP in the CT documentation (protocol, IB...)

<sup>14</sup> To be provided only where there is no tradename. This is the code designated by the sponsor which represents the name routinely used by the sponsor to identify the product in the CT documentation. For example, a code may be used for combinations of drugs or drugs and devices..

<sup>15</sup> Available from the Summary of Product Characteristics

<sup>16</sup> Chemical Abstracts Service.



**D.4. BIOLOGICAL / BIOTECHNOLOGICAL INVESTIGATIONAL MEDICINAL PRODUCTS INCLUDING VACCINES**

<b>D.4.1 Type of product</b>	
D.4.1.1 - Extractive	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.2 - Recombinant	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.3 - Vaccine	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.4 - GMO	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.5 - Plasma derived products	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.6 - Others	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.6.1 If others, specify :	

**D.5 SOMATIC CELL THERAPY INVESTIGATIONAL MEDICINAL PRODUCT (NO GENETIC MODIFICATION)**

<b>D.5.1 Origin of cells</b>	
D.5.1.1 - Autologous	yes <input type="checkbox"/> no <input type="checkbox"/>
D.5.1.2 - Allogeneic	yes <input type="checkbox"/> no <input type="checkbox"/>
D.5.1.3 - Xenogeneic	yes <input type="checkbox"/> no <input type="checkbox"/>
D.5.1.3.1 - If yes, specify species of origin :	

**D.5.2 Type of cells**

D.5.2.1 - Stem cells yes  no

D.5.2.2 - Differentiated cells yes  no

D.5.2.2.1 If yes, specify the type (e.g. keratinocytes, fibroblasts, chondrocytes,...) :

D.5.2.3 - Others : yes  no

D.5.2.3.1 If others, specify :

**D.6. GENE THERAPY INVESTIGATIONAL MEDICINAL PRODUCTS**

**D.6.1 Gene(s) of interest :**

**D.6.2 In vivo gene therapy:**

**D.6.3 Ex vivo gene therapy :**

**D.6.4 Type of gene transfer product**

D.6.4.1 - Nucleic acid (e.g. plasmid) : yes  no

If yes, specify

D.6.4.1.1 - Naked : yes  no

D.6.4.1.2 - Complexed : yes  no

D.6.4.2 - Viral vector : yes  no

D.6.4.2.1 If yes, specify the type : adenovirus, retrovirus, AAV, ...:

D.6.4.3 - Others : yes  no

D.6.4.3.1 If others, specify :

**D.6.5 Genetically modified cells :**

yes  no

If yes, specify origin of the cells :

D.6.5.1 - Autologous :

yes  no

D.6.5.2 - Allogeneic :

yes  no

D.6.5.3 - Xenogeneic :

yes  no

D.6.5.3.1 - If yes, specify species of origin :

D.6.5.4 - Other type of cells (hematopoietic stem cells, ...): yes  no

-If Yes specify :

**D.6.6 Comments on novel aspects of gene therapy investigational product if any (free text) :**

## D.1 IMP IDENTIFICATION

Indicate which of the following is described below, then repeat as necessary for each of the numbered IMPs to be used in the trial(assign numbers from 1-n):

- D.1.1 This refers to the IMP number :** PR4
- D.1.2 IMP being tested** ✓
- D.1.3 IMP used as a comparator**

*for placebo go directly to D.7*

**D.2 STATUS OF THE IMP.** If the IMP has a marketing authorisation in the Member State concerned by this application but the trade name and marketing authorisation holder are not fixed in the protocol, go to section D.2.2.

- D.2.1 Has the IMP to be used in the trial a marketing authorisation ?      yes  no
- D.2.1.1 If yes to D.2.1, specify for the product to be used in the trial :
- D.2.1.1.1 Trade name<sup>9</sup>
- D.2.1.1.2 Name of the MA holder<sup>9</sup>
- D.2.1.1.3 MA number (if MA granted by a Member State)<sup>9</sup>
- D.2.1.1.4 Is the IMP modified in relation to its MA ?      yes  no
- D.2.1.1.4.1 If Yes, please specify
- D.2.1.2 Which country granted the MA ?
- D.2.1.2.1 Is this the Member State concerned with this application ?      yes  no
- D.2.1.2.2 Is this another Member State ?      yes  no

**D.2.2 Situations where an IMP to be used in the CT has a MA in the MS concerned , but the protocol allows that any brand of the IMP with a MA in that MS be administered to the trial subjects and it is not possible to clearly identify the IMP(s) in advance of the trial start**

<p>D.2.2.1 In the protocol, is treatment defined only by active substance ?</p> <p>D.2.2.1.1 If Yes, give active substance in D.3.8 or D.3.9</p>	<p>yes <input checked="" type="checkbox"/> no <input type="checkbox"/></p>
<p>D.2.2.2 In the protocol, do treatment regimens allow different combinations of marketed products used according to local clinical practice at some or all investigator sites in the MS ?</p> <p>D.2.2.2.1 If Yes, give active substance in D.3.8 or D.3.9</p>	<p>yes <input checked="" type="checkbox"/> no <input type="checkbox"/></p>
<p>D.2.2.3 The products to be administered as IMPs are defined as belonging to an ATC group<sup>9</sup>.</p> <p>D.2.2.3.1 If Yes, give the ATC group of the applicable authorised codes in the ATC code field (level 3 or the level that can be defined) in D.3.3</p>	<p>yes <input checked="" type="checkbox"/> no <input type="checkbox"/></p>
<p>D.2.2.4 Other :</p>	<p>yes <input type="checkbox"/> no <input checked="" type="checkbox"/></p>
<p>D.2.2.4.1 If Yes, please specify :</p>	

**D.2.3 IMPD submitted :**

<p>D.2.3.1 Full IMPD</p>	<p>yes <input type="checkbox"/> no <input checked="" type="checkbox"/></p>
<p>D.2.3.2 Simplified IMPD<sup>10</sup>.</p>	<p>yes <input type="checkbox"/> no <input checked="" type="checkbox"/></p>
<p>D.2.3.3 Summary of product characteristics (SmPC) only</p>	<p>yes <input type="checkbox"/> no <input checked="" type="checkbox"/></p>

**D.2.4 Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community ?**

yes  no

D.2.4.1 If Yes, specify which Member States :

UNITED KINGDOM

**D.2.5 Has the IMP been designated in this indication as an orphan drug in the Community ?**

yes  no

D.2.5.1 If yes, give the orphan drug designation number<sup>11</sup>:

**D.2.6 Has the IMP been the subject of scientific advice related to this clinical trial ?**

yes  no

D.2.6.1 If Yes to D.2.6 please indicate source of advice and provide a copy in the CTA request :

D.2.6.1.1 From the CHMP <sup>12</sup>?

yes  no

D.2.6.1.2 From a MS competent authority ?

yes  no

<sup>9</sup> Available from the Summary of Product Characteristics

<sup>10</sup> Provide justification for using simplified dossier in the covering letter.

<sup>11</sup> According to the Community register on orphan medicinal products (Regulation (EC) n° 141/2000) :  
<http://pharmacos.eudra.org/F2/register/orphreg.htm>

<sup>12</sup> Committee for Medicinal Products for Human Use of the European Medicines Agency.

### D.3 DESCRIPTION OF THE IMP

**D.3.1 Product name where applicable<sup>13</sup> :** Dipyridamole

**D.3.2 Product code where applicable<sup>14</sup> :**

**D.3.3 ATC code, if officially registered<sup>15</sup> :** B01AC07

**D.3.4 Pharmaceutical form (use standard terms) :** Tablet

**D.3.5 Maximum duration of treatment of a subject according to the protocol :**

90 days (then to continue as normal treatment for stroke)

**D.3.6 Maximum dose allowed (specify : per day or total dose; units and route of administration) :**

400mg (200mg bd)

Per day or total dose : Per day

Units : 400 mg milligram(s)

Route of administration : Enteral Use

**D.3.7 Route of administration (use standard terms):** Enteral Use

Oral Use

---

**D.3.8 Name of each active substance (INN or proposed INN if available) :** DIPYRIDAMOLE

**D.3.9 Other available name for each active substance (CAS<sup>16</sup>, current sponsor code(s), other descriptive name, etc : provide all available) :**

- CAS 58322

- Current sponsor code(s)

- Other Descriptive name

**D.3.10 Strength (specify all strengths to be used) :**

D.3.10.1 - concentration unit : mg milligram(s)

D.3.10.2 - concentration type (“exact number”, “range”, “more than” or “up to”). range

D.3.10.3 - concentration number : 25 100



<sup>13</sup> To be provided only where there is no tradename. This is the name routinely used by the sponsor to identify the IMP in the CT documentation (protocol, IB...)

<sup>14</sup> To be provided only where there is no tradename. This is the code designated by the sponsor which represents the name routinely used by the sponsor to identify the product in the CT documentation. For example, a code may be used for combinations of drugs or drugs and devices..

<sup>15</sup> Available from the Summary of Product Characteristics

<sup>16</sup> Chemical Abstracts Service.



**D.4. BIOLOGICAL / BIOTECHNOLOGICAL INVESTIGATIONAL MEDICINAL PRODUCTS INCLUDING VACCINES**

<b>D.4.1 Type of product</b>	
D.4.1.1 - Extractive	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.2 - Recombinant	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.3 - Vaccine	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.4 - GMO	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.5 - Plasma derived products	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.6 - Others	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.6.1 If others, specify :	

**D.5 SOMATIC CELL THERAPY INVESTIGATIONAL MEDICINAL PRODUCT (NO GENETIC MODIFICATION)**

<b>D.5.1 Origin of cells</b>	
D.5.1.1 - Autologous	yes <input type="checkbox"/> no <input type="checkbox"/>
D.5.1.2 - Allogeneic	yes <input type="checkbox"/> no <input type="checkbox"/>
D.5.1.3 - Xenogeneic	yes <input type="checkbox"/> no <input type="checkbox"/>
D.5.1.3.1 - If yes, specify species of origin :	

**D.5.2 Type of cells**

D.5.2.1 - Stem cells yes  no

D.5.2.2 - Differentiated cells yes  no

D.5.2.2.1 If yes, specify the type (e.g. keratinocytes, fibroblasts, chondrocytes,...) :

D.5.2.3 - Others : yes  no

D.5.2.3.1 If others, specify :

**D.6. GENE THERAPY INVESTIGATIONAL MEDICINAL PRODUCTS**

**D.6.1 Gene(s) of interest :**

**D.6.2 In vivo gene therapy:**

**D.6.3 Ex vivo gene therapy :**

**D.6.4 Type of gene transfer product**

D.6.4.1 - Nucleic acid (e.g. plasmid) : yes  no

If yes, specify

D.6.4.1.1 - Naked : yes  no

D.6.4.1.2 - Complexed : yes  no

D.6.4.2 - Viral vector : yes  no

D.6.4.2.1 If yes, specify the type : adenovirus, retrovirus, AAV, ...:

D.6.4.3 - Others : yes  no

D.6.4.3.1 If others, specify :

**D.6.5 Genetically modified cells :**

yes  no

If yes, specify origin of the cells :

D.6.5.1 - Autologous :

yes  no

D.6.5.2 - Allogeneic :

yes  no

D.6.5.3 - Xenogeneic :

yes  no

D.6.5.3.1 - If yes, specify species of origin :

D.6.5.4 - Other type of cells (hematopoietic stem cells, ...): yes  no

-If Yes specify :

**D.6.6 Comments on novel aspects of gene therapy investigational product if any (free text) :**

## D.1 IMP IDENTIFICATION

Indicate which of the following is described below, then repeat as necessary for each of the numbered IMPs to be used in the trial(assign numbers from 1-n):

- D.1.1 This refers to the IMP number :** PR5
- D.1.2 IMP being tested** ✓
- D.1.3 IMP used as a comparator**

*for placebo go directly to D.7*

**D.2 STATUS OF THE IMP.** If the IMP has a marketing authorisation in the Member State concerned by this application but the trade name and marketing authorisation holder are not fixed in the protocol, go to section D.2.2.

D.2.1 Has the IMP to be used in the trial a marketing authorisation ?      yes  no

D.2.1.1 If yes to D.2.1, specify for the product to be used in the trial :

D.2.1.1.1 Trade name<sup>9</sup>

D.2.1.1.2 Name of the MA holder<sup>9</sup>

D.2.1.1.3 MA number (if MA granted by a Member State)<sup>9</sup>

D.2.1.1.4 Is the IMP modified in relation to its MA ?      yes  no

D.2.1.1.4.1 If Yes, please specify

D.2.1.2 Which country granted the MA ?

D.2.1.2.1 Is this the Member State concerned with this application ?      yes  no

D.2.1.2.2 Is this another Member State ?      yes  no

**D.2.2 Situations where an IMP to be used in the CT has a MA in the MS concerned , but the protocol allows that any brand of the IMP with a MA in that MS be administered to the trial subjects and it is not possible to clearly identify the IMP(s) in advance of the trial start**

D.2.2.1 In the protocol, is treatment defined only by active substance ?	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
D.2.2.1.1 If Yes, give active substance in D.3.8 or D.3.9	
D.2.2.2 In the protocol, do treatment regimens allow different combinations of marketed products used according to local clinical practice at some or all investigator sites in the MS ?	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
D.2.2.2.1 If Yes, give active substance in D.3.8 or D.3.9	
D.2.2.3 The products to be administered as IMPs are defined as belonging to an ATC group <sup>9</sup> .	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
D.2.2.3.1 If Yes, give the ATC group of the applicable authorised codes in the ATC code field (level 3 or the level that can be defined) in D.3.3	
D.2.2.4 Other :	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
D.2.2.4.1 If Yes, please specify :	

**D.2.3 IMPD submitted :**

D.2.3.1 Full IMPD	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
D.2.3.2 Simplified IMPD <sup>10</sup> .	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
D.2.3.3 Summary of product characteristics (SmPC) only	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>

**D.2.4 Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community ?**

yes  no

D.2.4.1 If Yes, specify which Member States :  
UNITED KINGDOM

**D.2.5 Has the IMP been designated in this indication as an orphan drug in the Community ?**

yes  no

D.2.5.1 If yes, give the orphan drug designation number<sup>11</sup>:

**D.2.6 Has the IMP been the subject of scientific advice related to this clinical trial ?**

yes  no

D.2.6.1 If Yes to D.2.6 please indicate source of advice and provide a copy in the CTA request :

D.2.6.1.1 From the CHMP <sup>12</sup>?

yes  no

D.2.6.1.2 From a MS competent authority ?

yes  no

<sup>9</sup> Available from the Summary of Product Characteristics

<sup>10</sup> Provide justification for using simplified dossier in the covering letter.

<sup>11</sup> According to the Community register on orphan medicinal products (Regulation (EC) n° 141/2000) :  
<http://pharmacos.eudra.org/F2/register/orphreg.htm>

<sup>12</sup> Committee for Medicinal Products for Human Use of the European Medicines Agency.

### D.3 DESCRIPTION OF THE IMP

**D.3.1 Product name where applicable<sup>13</sup> :** Dipyridamole

**D.3.2 Product code where applicable<sup>14</sup> :**

**D.3.3 ATC code, if officially registered<sup>15</sup> :** B01AC07

**D.3.4 Pharmaceutical form (use standard terms) :** Oral Suspension

**D.3.5 Maximum duration of treatment of a subject according to the protocol :**

90 days (then to continue as normal treatment for stroke)

**D.3.6 Maximum dose allowed (specify : per day or total dose; units and route of administration) :**

225mg (75mg tds)

Per day or total dose : Per day

Units : 225 mg milligram(s)

Route of administration : Enteral Use

**D.3.7 Route of administration (use standard terms):** Enteral Use

Oral Use

---

**D.3.8 Name of each active substance (INN or proposed INN if available) :** DIPYRIDAMOLE

**D.3.9 Other available name for each active substance (CAS<sup>16</sup>, current sponsor code(s), other descriptive name, etc : provide all available) :**

- CAS 58322

- Current sponsor code(s)


- Other Descriptive name

**D.3.10 Strength (specify all strengths to be used) :**

D.3.10.1 - concentration unit : mg/ml milligram(s)/millilitre

D.3.10.2 - concentration type (“exact number”, “range”, “more than” or “up to”). equal

D.3.10.3 - concentration number : 10



<sup>13</sup> To be provided only where there is no tradename. This is the name routinely used by the sponsor to identify the IMP in the CT documentation (protocol, IB...)

<sup>14</sup> To be provided only where there is no tradename. This is the code designated by the sponsor which represents the name routinely used by the sponsor to identify the product in the CT documentation. For example, a code may be used for combinations of drugs or drugs and devices..

<sup>15</sup> Available from the Summary of Product Characteristics

<sup>16</sup> Chemical Abstracts Service.



**D.4. BIOLOGICAL / BIOTECHNOLOGICAL INVESTIGATIONAL MEDICINAL PRODUCTS INCLUDING VACCINES**

<b>D.4.1 Type of product</b>	
D.4.1.1 - Extractive	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.2 - Recombinant	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.3 - Vaccine	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.4 - GMO	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.5 - Plasma derived products	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.6 - Others	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.6.1 If others, specify :	

**D.5 SOMATIC CELL THERAPY INVESTIGATIONAL MEDICINAL PRODUCT (NO GENETIC MODIFICATION)**

<b>D.5.1 Origin of cells</b>	
D.5.1.1 - Autologous	yes <input type="checkbox"/> no <input type="checkbox"/>
D.5.1.2 - Allogeneic	yes <input type="checkbox"/> no <input type="checkbox"/>
D.5.1.3 - Xenogeneic	yes <input type="checkbox"/> no <input type="checkbox"/>
D.5.1.3.1 - If yes, specify species of origin :	

**D.5.2 Type of cells**

D.5.2.1 - Stem cells yes  no

D.5.2.2 - Differentiated cells yes  no

D.5.2.2.1 If yes, specify the type (e.g. keratinocytes, fibroblasts, chondrocytes,...) :

D.5.2.3 - Others : yes  no

D.5.2.3.1 If others, specify :

**D.6. GENE THERAPY INVESTIGATIONAL MEDICINAL PRODUCTS**

**D.6.1 Gene(s) of interest :**

**D.6.2 In vivo gene therapy:**

**D.6.3 Ex vivo gene therapy :**

**D.6.4 Type of gene transfer product**

D.6.4.1 - Nucleic acid (e.g. plasmid) : yes  no

If yes, specify

D.6.4.1.1 - Naked : yes  no

D.6.4.1.2 - Complexed : yes  no

D.6.4.2 - Viral vector : yes  no

D.6.4.2.1 If yes, specify the type : adenovirus, retrovirus, AAV, ...:

D.6.4.3 - Others : yes  no

D.6.4.3.1 If others, specify :

**D.6.5 Genetically modified cells :**

yes  no

If yes, specify origin of the cells :

D.6.5.1 - Autologous :

yes  no

D.6.5.2 - Allogeneic :

yes  no

D.6.5.3 - Xenogeneic :

yes  no

D.6.5.3.1 - If yes, specify species of origin :

D.6.5.4 - Other type of cells (hematopoietic stem cells, ...): yes  no

-If Yes specify :

**D.6.6 Comments on novel aspects of gene therapy investigational product if any (free text) :**

## D.1 IMP IDENTIFICATION

Indicate which of the following is described below, then repeat as necessary for each of the numbered IMPs to be used in the trial(assign numbers from 1-n):

- D.1.1 This refers to the IMP number :** PR6
- D.1.2 IMP being tested** ✓
- D.1.3 IMP used as a comparator**

*for placebo go directly to D.7*

**D.2 STATUS OF THE IMP.** If the IMP has a marketing authorisation in the Member State concerned by this application but the trade name and marketing authorisation holder are not fixed in the protocol, go to section D.2.2.

- D.2.1 Has the IMP to be used in the trial a marketing authorisation ?      yes  no
- D.2.1.1 If yes to D.2.1, specify for the product to be used in the trial :
- D.2.1.1.1 Trade name<sup>9</sup>
- D.2.1.1.2 Name of the MA holder<sup>9</sup>
- D.2.1.1.3 MA number (if MA granted by a Member State)<sup>9</sup>
- D.2.1.1.4 Is the IMP modified in relation to its MA ?      yes  no
- D.2.1.1.4.1 If Yes, please specify
- D.2.1.2 Which country granted the MA ?
- D.2.1.2.1 Is this the Member State concerned with this application ?      yes  no
- D.2.1.2.2 Is this another Member State ?      yes  no

**D.2.2 Situations where an IMP to be used in the CT has a MA in the MS concerned , but the protocol allows that any brand of the IMP with a MA in that MS be administered to the trial subjects and it is not possible to clearly identify the IMP(s) in advance of the trial start**

D.2.2.1 In the protocol, is treatment defined only by active substance ?	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
D.2.2.1.1 If Yes, give active substance in D.3.8 or D.3.9	
D.2.2.2 In the protocol, do treatment regimens allow different combinations of marketed products used according to local clinical practice at some or all investigator sites in the MS ?	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
D.2.2.2.1 If Yes, give active substance in D.3.8 or D.3.9	
D.2.2.3 The products to be administered as IMPs are defined as belonging to an ATC group <sup>9</sup> .	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
D.2.2.3.1 If Yes, give the ATC group of the applicable authorised codes in the ATC code field (level 3 or the level that can be defined) in D.3.3	
D.2.2.4 Other :	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
D.2.2.4.1 If Yes, please specify :	

**D.2.3 IMPD submitted :**

D.2.3.1 Full IMPD	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
D.2.3.2 Simplified IMPD <sup>10</sup> .	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
D.2.3.3 Summary of product characteristics (SmPC) only	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>

**D.2.4 Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community ?**

yes  no

D.2.4.1 If Yes, specify which Member States :  
UNITED KINGDOM

**D.2.5 Has the IMP been designated in this indication as an orphan drug in the Community ?**

yes  no

D.2.5.1 If yes, give the orphan drug designation number<sup>11</sup>:

**D.2.6 Has the IMP been the subject of scientific advice related to this clinical trial ?**

yes  no

D.2.6.1 If Yes to D.2.6 please indicate source of advice and provide a copy in the CTA request :

D.2.6.1.1 From the CHMP <sup>12</sup>?

yes  no

D.2.6.1.2 From a MS competent authority ?

yes  no

<sup>9</sup> Available from the Summary of Product Characteristics

<sup>10</sup> Provide justification for using simplified dossier in the covering letter.

<sup>11</sup> According to the Community register on orphan medicinal products (Regulation (EC) n° 141/2000) :  
<http://pharmacos.eudra.org/F2/register/orphreg.htm>

<sup>12</sup> Committee for Medicinal Products for Human Use of the European Medicines Agency.

### D.3 DESCRIPTION OF THE IMP

**D.3.1 Product name where applicable<sup>13</sup> :** Dipyridamole

**D.3.2 Product code where applicable<sup>14</sup> :**

**D.3.3 ATC code, if officially registered<sup>15</sup> :** B01AC07

**D.3.4 Pharmaceutical form (use standard terms) :** Soft Capsule

**D.3.5 Maximum duration of treatment of a subject according to the protocol :**

90 days (then to continue as normal treatment for stroke)

**D.3.6 Maximum dose allowed (specify : per day or total dose; units and route of administration) :**

400mg (200mg modified release bd)

Per day or total dose : Per day

Units : 225 mg milligram(s)

Route of administration : Oral Use

**D.3.7 Route of administration (use standard terms):** Oral Use

---

**D.3.8 Name of each active substance (INN or proposed INN if available) :** DIPYRIDAMOLE

**D.3.9 Other available name for each active substance (CAS<sup>16</sup>, current sponsor code(s), other descriptive name, etc : provide all available) :**

- CAS 58322

- Current sponsor code(s)

- Other Descriptive name

**D.3.10 Strength (specify all strengths to be used) :**

D.3.10.1 - concentration unit : mg milligram(s)

D.3.10.2 - concentration type (“exact number”, “range”, “more than” or “up to”). equal

D.3.10.3 - concentration number : 200mg



<sup>13</sup> To be provided only where there is no tradename. This is the name routinely used by the sponsor to identify the IMP in the CT documentation (protocol, IB...)

<sup>14</sup> To be provided only where there is no tradename. This is the code designated by the sponsor which represents the name routinely used by the sponsor to identify the product in the CT documentation. For example, a code may be used for combinations of drugs or drugs and devices..

<sup>15</sup> Available from the Summary of Product Characteristics

<sup>16</sup> Chemical Abstracts Service.



**D.4. BIOLOGICAL / BIOTECHNOLOGICAL INVESTIGATIONAL MEDICINAL PRODUCTS INCLUDING VACCINES**

<b>D.4.1 Type of product</b>	
D.4.1.1 - Extractive	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.2 - Recombinant	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.3 - Vaccine	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.4 - GMO	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.5 - Plasma derived products	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.6 - Others	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.6.1 If others, specify :	

**D.5 SOMATIC CELL THERAPY INVESTIGATIONAL MEDICINAL PRODUCT (NO GENETIC MODIFICATION)**

<b>D.5.1 Origin of cells</b>	
D.5.1.1 - Autologous	yes <input type="checkbox"/> no <input type="checkbox"/>
D.5.1.2 - Allogeneic	yes <input type="checkbox"/> no <input type="checkbox"/>
D.5.1.3 - Xenogeneic	yes <input type="checkbox"/> no <input type="checkbox"/>
D.5.1.3.1 - If yes, specify species of origin :	

**D.5.2 Type of cells**

D.5.2.1 - Stem cells yes  no

D.5.2.2 - Differentiated cells yes  no

D.5.2.2.1 If yes, specify the type (e.g. keratinocytes, fibroblasts, chondrocytes,...) :

D.5.2.3 - Others : yes  no

D.5.2.3.1 If others, specify :

**D.6. GENE THERAPY INVESTIGATIONAL MEDICINAL PRODUCTS**

**D.6.1 Gene(s) of interest :**

**D.6.2 In vivo gene therapy:**

**D.6.3 Ex vivo gene therapy :**

**D.6.4 Type of gene transfer product**

D.6.4.1 - Nucleic acid (e.g. plasmid) : yes  no

If yes, specify

D.6.4.1.1 - Naked : yes  no

D.6.4.1.2 - Complexed : yes  no

D.6.4.2 - Viral vector : yes  no

D.6.4.2.1 If yes, specify the type : adenovirus, retrovirus, AAV, ...:

D.6.4.3 - Others : yes  no

D.6.4.3.1 If others, specify :

**D.6.5 Genetically modified cells :**

yes  no

If yes, specify origin of the cells :

D.6.5.1 - Autologous :

yes  no

D.6.5.2 - Allogeneic :

yes  no

D.6.5.3 - Xenogeneic :

yes  no

D.6.5.3.1 - If yes, specify species of origin :

D.6.5.4 - Other type of cells (hematopoietic stem cells, ...): yes  no

-If Yes specify :

**D.6.6 Comments on novel aspects of gene therapy investigational product if any (free text) :**

## D.1 IMP IDENTIFICATION

Indicate which of the following is described below, then repeat as necessary for each of the numbered IMPs to be used in the trial(assign numbers from 1-n):

- D.1.1 This refers to the IMP number :** PR7
- D.1.2 IMP being tested** ✓
- D.1.3 IMP used as a comparator**

*for placebo go directly to D.7*

**D.2 STATUS OF THE IMP.** If the IMP has a marketing authorisation in the Member State concerned by this application but the trade name and marketing authorisation holder are not fixed in the protocol, go to section D.2.2.

- D.2.1 Has the IMP to be used in the trial a marketing authorisation ?      yes  no
- D.2.1.1 If yes to D.2.1, specify for the product to be used in the trial :
- D.2.1.1.1 Trade name<sup>9</sup>
- D.2.1.1.2 Name of the MA holder<sup>9</sup>
- D.2.1.1.3 MA number (if MA granted by a Member State)<sup>9</sup>
- D.2.1.1.4 Is the IMP modified in relation to its MA ?      yes  no
- D.2.1.1.4.1 If Yes, please specify
- D.2.1.2 Which country granted the MA ?
- D.2.1.2.1 Is this the Member State concerned with this application ?      yes  no
- D.2.1.2.2 Is this another Member State ?      yes  no

**D.2.2 Situations where an IMP to be used in the CT has a MA in the MS concerned , but the protocol allows that any brand of the IMP with a MA in that MS be administered to the trial subjects and it is not possible to clearly identify the IMP(s) in advance of the trial start**

<p>D.2.2.1 In the protocol, is treatment defined only by active substance ?</p> <p>D.2.2.1.1 If Yes, give active substance in D.3.8 or D.3.9</p>	<p>yes <input checked="" type="checkbox"/> no <input type="checkbox"/></p>
<p>D.2.2.2 In the protocol, do treatment regimens allow different combinations of marketed products used according to local clinical practice at some or all investigator sites in the MS ?</p> <p>D.2.2.2.1 If Yes, give active substance in D.3.8 or D.3.9</p>	<p>yes <input checked="" type="checkbox"/> no <input type="checkbox"/></p>
<p>D.2.2.3 The products to be administered as IMPs are defined as belonging to an ATC group<sup>9</sup>.</p> <p>D.2.2.3.1 If Yes, give the ATC group of the applicable authorised codes in the ATC code field (level 3 or the level that can be defined) in D.3.3</p>	<p>yes <input checked="" type="checkbox"/> no <input type="checkbox"/></p>
<p>D.2.2.4 Other :</p>	<p>yes <input type="checkbox"/> no <input checked="" type="checkbox"/></p>
<p>D.2.2.4.1 If Yes, please specify :</p>	

**D.2.3 IMPD submitted :**

<p>D.2.3.1 Full IMPD</p>	<p>yes <input type="checkbox"/> no <input checked="" type="checkbox"/></p>
<p>D.2.3.2 Simplified IMPD<sup>10</sup>.</p>	<p>yes <input type="checkbox"/> no <input checked="" type="checkbox"/></p>
<p>D.2.3.3 Summary of product characteristics (SmPC) only</p>	<p>yes <input type="checkbox"/> no <input checked="" type="checkbox"/></p>

**D.2.4 Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community ?**

yes  no

D.2.4.1 If Yes, specify which Member States :

UNITED KINGDOM

**D.2.5 Has the IMP been designated in this indication as an orphan drug in the Community ?**

yes  no

D.2.5.1 If yes, give the orphan drug designation number<sup>11</sup>:

**D.2.6 Has the IMP been the subject of scientific advice related to this clinical trial ?**

yes  no

D.2.6.1 If Yes to D.2.6 please indicate source of advice and provide a copy in the CTA request :

D.2.6.1.1 From the CHMP <sup>12</sup>?

yes  no

D.2.6.1.2 From a MS competent authority ?

yes  no

<sup>9</sup> Available from the Summary of Product Characteristics

<sup>10</sup> Provide justification for using simplified dossier in the covering letter.

<sup>11</sup> According to the Community register on orphan medicinal products (Regulation (EC) n° 141/2000) :  
<http://pharmacos.eudra.org/F2/register/orphreg.htm>

<sup>12</sup> Committee for Medicinal Products for Human Use of the European Medicines Agency.

### D.3 DESCRIPTION OF THE IMP

**D.3.1 Product name where applicable<sup>13</sup> :** Clopidogrel

**D.3.2 Product code where applicable<sup>14</sup> :**

**D.3.3 ATC code, if officially registered<sup>15</sup> :** B01AC04

**D.3.4 Pharmaceutical form (use standard terms) :** Tablet

**D.3.5 Maximum duration of treatment of a subject according to the protocol :**

28

**D.3.6 Maximum dose allowed (specify : per day or total dose; units and route of administration) :**

300mg loading dose then 75mg daily

Per day or total dose : Per day

Units : 75 mg milligram(s)

Route of administration : Enteral Use

**D.3.7 Route of administration (use standard terms):** Enteral Use

Oral Use

---

**D.3.8 Name of each active substance (INN or proposed INN if available) :** CLOPIDOGREL

**D.3.9 Other available name for each active substance (CAS<sup>16</sup>, current sponsor code(s), other descriptive name, etc : provide all available) :**

- CAS 94188848

- Current sponsor code(s)

- Other Descriptive name

**D.3.10 Strength (specify all strengths to be used) :**

D.3.10.1 - concentration unit : mg milligram(s)

D.3.10.2 - concentration type (“exact number”, “range”, “more than” or “up to”). equal

D.3.10.3 - concentration number : 75



<sup>13</sup> To be provided only where there is no tradename. This is the name routinely used by the sponsor to identify the IMP in the CT documentation (protocol, IB...)

<sup>14</sup> To be provided only where there is no tradename. This is the code designated by the sponsor which represents the name routinely used by the sponsor to identify the product in the CT documentation. For example, a code may be used for combinations of drugs or drugs and devices..

<sup>15</sup> Available from the Summary of Product Characteristics

<sup>16</sup> Chemical Abstracts Service.



**D.4. BIOLOGICAL / BIOTECHNOLOGICAL INVESTIGATIONAL MEDICINAL PRODUCTS INCLUDING VACCINES**

<b>D.4.1 Type of product</b>	
D.4.1.1 - Extractive	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.2 - Recombinant	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.3 - Vaccine	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.4 - GMO	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.5 - Plasma derived products	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.6 - Others	yes <input type="checkbox"/> no <input type="checkbox"/>
D.4.1.6.1 If others, specify :	

**D.5 SOMATIC CELL THERAPY INVESTIGATIONAL MEDICINAL PRODUCT (NO GENETIC MODIFICATION)**

<b>D.5.1 Origin of cells</b>	
D.5.1.1 - Autologous	yes <input type="checkbox"/> no <input type="checkbox"/>
D.5.1.2 - Allogeneic	yes <input type="checkbox"/> no <input type="checkbox"/>
D.5.1.3 - Xenogeneic	yes <input type="checkbox"/> no <input type="checkbox"/>
D.5.1.3.1 - If yes, specify species of origin :	

**D.5.2 Type of cells**

D.5.2.1 - Stem cells yes  no

D.5.2.2 - Differentiated cells yes  no

D.5.2.2.1 If yes, specify the type (e.g. keratinocytes, fibroblasts, chondrocytes,...) :

D.5.2.3 - Others : yes  no

D.5.2.3.1 If others, specify :

**D.6. GENE THERAPY INVESTIGATIONAL MEDICINAL PRODUCTS**

**D.6.1 Gene(s) of interest :**

**D.6.2 In vivo gene therapy:**

**D.6.3 Ex vivo gene therapy :**

**D.6.4 Type of gene transfer product**

D.6.4.1 - Nucleic acid (e.g. plasmid) : yes  no

If yes, specify

D.6.4.1.1 - Naked : yes  no

D.6.4.1.2 - Complexed : yes  no

D.6.4.2 - Viral vector : yes  no

D.6.4.2.1 If yes, specify the type : adenovirus, retrovirus, AAV, ...:

D.6.4.3 - Others : yes  no

D.6.4.3.1 If others, specify :

**D.6.5 Genetically modified cells :**

yes  no

If yes, specify origin of the cells :

D.6.5.1 - Autologous :

yes  no

D.6.5.2 - Allogeneic :

yes  no

D.6.5.3 - Xenogeneic :

yes  no

D.6.5.3.1 - If yes, specify species of origin :

D.6.5.4 - Other type of cells (hematopoietic stem cells, ...): yes  no

-If Yes specify :

**D.6.6 Comments on novel aspects of gene therapy investigational product if any (free text) :**

**D.7 INFORMATION ON PLACEBO** (if relevant repeat as necessary)

D.7.1 Is there a placebo:

yes  no

D.7.2 This refers to Placebo number (.....)

D.7.3 Pharmaceutical form :

D.7.4 Route of administration :

D.7.5 Which IMP is it a placebo for? Specify IMP Number(s)  
from D.1.1

D.7.5.1 Composition, apart from the active substance(s) :

D.7.5.2 - is it otherwise identical to the IMP?

yes  no

D.7.5.2.1- if not, specify major ingredients :

## D.8 SITE WHERE THE QUALIFIED PERSON CERTIFIES BATCH RELEASE<sup>18</sup>

*This section is dedicated to **finished** IMPs i.e. medicinal products randomised, packaged, labelled and certified for use in the clinical trial. If there is more than one site or more than one IMP is certified, use extra pages and give each IMP its number from Section D.1.1 or D.7.2. In the case of multiple sites indicate the product certified by each site.*

### D.8.1 Do not fill in section 8.2 for an IMP that:

- Has an MA in the EU **and**
- Is sourced from the EU market **and**
- Is used in the trial without modification (eg not overencapsulated) **and**
- The packaging and labelling is carried out for local use only as per article 9.2 of the Directive 2005/28/EC (GCP Directive)

If all these conditions are met tick  and list the number(s) of each IMP including placebo from sections D.1.1 and D.7.2. to which this applies

---

PR1

PR2

PR3

PR4

PR5

PR6

PR7

<sup>18</sup>In accordance with paragraph 38 of Annex 13 of Volume 4 of the Rules Governing Medical Products in the European Union

**D.8.2 Who is responsible in the Community for the certification of the finished IMP ? :**

**This site is responsible for certification of (list the number(s) of each IMP including placebo concerned from sections D.1.1 and D.7.2) :**

Please tick the appropriate box:

D.8.2.1 - Manufacturer

D.8.2.2 - Importer

D.8.2.3 Name of the organisation :

D.8.2.3.1 Address :

D.8.2.4 - Give the manufacturing authorisation number :

D.8.2.4.1 If no authorisation, give the reasons :

*Where the product does not have a MA in the EU but is supplied in bulk and final packaging and labelling for local use is carried out in accordance with article 9.2 of Directive 2005/28/EC/(GCP Directive) then enter the site where the product was finally certified for release by the Qualified Person for use in the clinical trial at D.8.2 above*

## E. GENERAL INFORMATION ON THE TRIAL

The section should be used to provide information about the aims, scope and design of the trial. When the protocol includes a sub-study in the MS concerned section E.2.3 should be completed providing information about the sub-study. To identify it check the sub-study in the 'Objective of the trial' question below.

### E.1 Medical condition or disease under investigation

E.1.1 Specify the medical condition(s) to be investigated<sup>19</sup> (free text) :

Ischaemic stroke and TIA (transient ischaemic attack)

E.1.2 MedDRA version, level, term and classification code<sup>20</sup> (repeat as necessary) :

Version	Level	Code	Term
9.1	LLT	10042244	Stroke
9.1	LLT	10044390	Transient ischaemic attack

E.1.3 Is any of the conditions to be studied a rare disease<sup>21</sup> ?      yes  no

### E.2 Objective of the trial

E.2.1 Main objective :

To assess the safety of short-term administration (1 month) of triple antiplatelet therapy (aspirin, dipyridamole and clopidogrel) versus standard dual therapy (aspirin and dipyridamole) in patients with very recent ischaemic stroke or TIA.

E.2.2 Secondary objectives :

- To further assess, in high risk patients with stroke/TIA, whether the addition of C to AD:
  - Is feasible to administer acutely and tolerable to take for 1 month,
  - Is superior in respect of surrogate markers assessed as emboli (with transcranial doppler) and platelet function
  - Improves functional outcome
- To assess whether ordinal outcomes are superior to binary events

E.2.3 Is there a sub-study ?      yes  no

E.2.3.1 If Yes, give the full title, date and version of each sub-study and their related objectives :

<sup>19</sup> In the case of healthy volunteer trial, the intended indication for the product under development should be provided.

<sup>20</sup> Applicants are encouraged to provide the MedDRA lower level term if applicable and classification code. These can be accessed from the EMEA EudraCT website (<http://eudract.emea.europa.eu/>)

<sup>21</sup> Points to consider on the calculation and reporting of the prevalence of a condition for Orphan drug designation : COM/436/01 ([www.emea.europa.eu/htms/human/comp/orphaapp.htm](http://www.emea.europa.eu/htms/human/comp/orphaapp.htm))

### **E.3 Principal inclusion criteria (list the most important)**

Adults at high risk of recurrent ischaemic stroke:

1. Acute non-cardioembolic ischaemic stroke (<48 hours of onset);
2. Acute TIA (<48 hours of onset) with one or more of: crescendo TIA (>1 TIA within 1 week), and/or admitted on dual antiplatelet therapy (AD, AC, CD), and/or with an ABCD2 score >5 (stroke rate at 13 weeks>10%).

### **E.4 Principal exclusion criteria (list the most important)**

1. Age<40;
  2. Motor weakness lasting <30 minutes (pure sensory, vertigo or dizziness, speech or visual disturbance symptoms without weakness are excluded);
  3. Patients with contraindications to, or intolerance of, A, C or D;
  4. Pre-morbid dependency (mRS>3);
  5. No enteral access;
  6. Parenchymal haemorrhagic transformation (PH I/II), subarachnoid haemorrhage or other non ischaemic cause for weakness;
  7. TIA not fulfilling inclusion criteria
  8. Definite need for, or currently on triple antiplatelet therapy or anticoagulation;
  9. Indication for, or received (in last week), thrombolysis;
  10. Presumed cardioembolic stroke (e.g. AF, recent MI, or other conditions need for anticoagulation);
  11. Severe high BP (BP>185/110 mmHg);
  12. Bleeding within 1 year (e.g. peptic ulcer, intracerebral haemorrhage); Planned surgery during 3 month follow-up (e.g. carotid endarterectomy).
  13. Concomitant acute coronary syndrome;
  14. Stroke secondary to a procedure (e.g. carotid or coronary intervention);
  15. Planned surgery during first month post stroke (e.g. carotid endarterectomy);
  16. Coma (GCS<8)
  17. Non-stroke life expectancy<6 months;
  18. Dementia
  19. Participation in another drug trial concurrently or within 30 days. (Patients may be randomised into observational studies or non-drug trials)
  20. Not available for follow-up e.g. no fixed address, overseas visitor
  21. Females of childbearing potential, pregnancy or breastfeeding
- [Note: Clopidogrel will be stopped around procedures that become necessary after enrolment].

<b>E.5 Primary end point(s) :</b>
This start-up phase will assess ordinal bleeding (fatal/major/minor/none <sup>26</sup> ) at 35 days (end of treatment) as adjudicated by an independent blinded panel.

<b>E.6 Scope of the trial – Tick all boxes where applicable</b>	
E.6.1 - Diagnosis	<input type="checkbox"/>
E.6.2 - Prophylaxis	<input type="checkbox"/>
E.6.3 - Therapy	<input checked="" type="checkbox"/>
E.6.4 - Safety	<input checked="" type="checkbox"/>
E.6.5 - Efficacy	<input checked="" type="checkbox"/>
E.6.6 - Pharmacokinetic	<input type="checkbox"/>
E.6.7 - Pharmacodynamic	<input type="checkbox"/>
E.6.8 - Bioequivalence	<input type="checkbox"/>
E.6.9 - Dose Response	<input type="checkbox"/>
E.6.10 - Pharmacogenetic	<input type="checkbox"/>
E.6.11 - Pharmacogenomic	<input type="checkbox"/>
E.6.12 - Pharmacoeconomic	<input type="checkbox"/>
E.6.13 - Others	<input type="checkbox"/>
E.6.13.1 If others, specify :	

<b>E.7 Trial type<sup>22</sup> and phase</b>	
E.7.1 Human pharmacology (Phase I)	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>

Is it:

- E.7.1.1 First administration to humans                      yes  no
- E.7.1.2 Bioequivalence study                                      yes  no
- E.7.1.3 Other    yes  no
- E.7.1.3.1 If Other, please specify :
- E.7.2 Therapeutic exploratory (Phase II )                      yes  no
- E.7.3 Therapeutic confirmatory (Phase III)                      yes  no
- E.7.4 Therapeutic use (Phase IV)                                      yes  no

## E.8 Design of the trial

E.8.1 Controlled :                      yes  no

• If yes, specify :

E.8.1.2 Open :                      yes  no

E.8.1.1 Randomised :                      yes  no

E.8.1.3 Single blind :                      yes  no

E.8.1.4 Double blind :                      yes  no

E.8.1.5 Parallel group :                      yes  no

E.8.1.6 Cross over :                      yes  no

E.8.1.7 Other :                      yes  no

E.8.1.7.1 If yes to other, specify :                      Assessor blinded

E.8.2 • If Controlled specify the comparator :

E.8.2.1 - Other medicinal product(s)                      yes  no

E.8.2.2 - Placebo                      yes  no

E.8.2.3 - Other                      yes  no

E.8.2.3.1 If yes to other specify :

E.8.3 Single site in the Member State concerned (see also section G) :                      yes  no

E.8.4 Multiple sites in the Member State concerned (see also section G) :                      yes  no

E.8.4.1 Number of sites anticipated in the Member State concerned :                      20

E.8.5 Multiple Member States :                      yes  no

E.8.5.1 Number of sites anticipated in the Community :

E.8.6 Does this trial involve countries outside the EU ?

yes  no

E.8.7 Does this trial have a data monitoring committee ?

yes  no

---

<sup>22</sup> The descriptions of the trial types provided are those recommended in preference to Phases. See page 5 of Community guideline CPMP/ICH/291/95. The development of a new indication after initial approval of a medicine should be considered as a new development plan.

**E.8.8 Definition of the end of trial and justification, in the case where it is not the last visit of the last subject undergoing the trial :<sup>23</sup>**

The last visit of the last subject undergoing the trial. This trial (350 subjects) will form the start-up phase and run into a larger trial of the same design of up to 5000 patients. Separate funding and regulatory applications will be made for this.

**E.8.9 Initial estimate of the duration of the trial<sup>24</sup> (years, months and days):**

E.8.9.1 - in the MS concerned	3	years	months	days
E.8.9.2 - in all countries concerned by the trial	3	years	months	days

<sup>23</sup> If not provided in the protocol

<sup>24</sup> From the 1st inclusion until the last visit of the last subject

## F. POPULATION OF TRIAL SUBJECTS

<b>F.1 Age Span</b>	
F.1.1 Less than 18 years	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
If yes, specify:	
F.1.1.1 In Utero	yes <input type="checkbox"/> no <input type="checkbox"/>
F.1.1.2 Preterm Newborn Infants (up to gestational age < 37 weeks)	yes <input type="checkbox"/> no <input type="checkbox"/>
F.1.1.3 Newborn (0-27 days)	yes <input type="checkbox"/> no <input type="checkbox"/>
F.1.1.4 Infant and toddler (28 days - 23 months)	yes <input type="checkbox"/> no <input type="checkbox"/>
F.1.1.5 Children (2-11 years)	yes <input type="checkbox"/> no <input type="checkbox"/>
F.1.1.6 Adolescent (12-17 years)	yes <input type="checkbox"/> no <input type="checkbox"/>
F.1.2 Adult (18-65 years)	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
F.1.3 Elderly (> 65 years)	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
<b>F.2 Gender</b>	
F.2.1 Female	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
F.2.3 Male	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>

<b>F.3 Group of trial subjects</b>	
F.3.1 Healthy volunteers	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
F.3.2 Patients	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
F.3.3 Specific vulnerable populations	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
F.3.3.1 - women of child bearing potential	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
F.3.3.2 - women of childbearing potential using contraception	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
F.3.3.3 - pregnant women	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
F.3.3.4 - nursing women	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
F.3.3.5 - emergency situation	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
F.3.3.6 - subjects incapable of giving consent personally	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
F.3.3.6.1 If yes, specify :	
Patients with a stroke are often incapacitated through confusion, dysphasia or coma.	

F.3.3.7 - others :

yes  no

F.3.3.7.1 If yes, specify :

Elderly patients

**F.4 Planned number of subjects to be included :**

F.4.1 - in the Member State :350

F.4.2 For a multinational trial:

F.4.2.1 - in the Community :

F.4.2.2 - in the whole clinical trial :

**F.5 Plans for treatment or care after a subject has ended his/her participation in the trial<sup>25</sup> If it is different from the expected normal treatment of that condition, please specify (free text) :**

---

<sup>25</sup> If not already provided in the protocol

**G. CLINICAL TRIAL SITES/INVESTIGATORS IN THE MEMBER STATE CONCERNED BY THIS REQUEST**

**G.1. Coordinating investigator (*for multicentre trial*) and principal investigator (*for single centre trial*)**

G.1.1 and G.1.2 and G.1.3  
Name :

Philip Bath

G.1.4 Qualification  
(MD.....)

MBBS, MD, FRCP, FRCPath

G.1.5 Professional address:

Division of Stroke Medicine

University of Nottingham

CSB, City Hospital Campus

Nottingham

NG5 1PB

UNITED KINGDOM

**G.2. Principal investigators (for multicentre trial; where necessary, use additional forms)**

G.2.1 and G.2.2 and G.2.3  
Name :

Tom Robinson

G.2.4 Qualification  
(MD.....)

MBBS, MD, FRCP

G.2.5 Professional address :

Dept of Cardiovascular Sciences

University Hospitals of Leicester

UHL NHS Trust, Gwendolen Rd

Leicester

LE4 4PW

UNITED KINGDOM

**G.2. Principal investigators (for multicentre trial; where necessary, use additional forms)**

G.2.1 and G.2.2 and G.2.3  
Name :

Graham Venables

G.2.4 Qualification  
(MD.....)

BA, BM BCh, DM, FRCP, FRCOphth

G.2.5 Professional address :

Neurology Dept

Sheffield Teaching Hospitals

Royal Hampshire Hospital

Sheffield

S10 2JF

UNITED KINGDOM

**G.2. Principal investigators (for multicentre trial; where necessary, use additional forms)**

G.2.1 and G.2.2 and G.2.3  
Name :

Khulood Muhiddin

G.2.4 Qualification  
(MD.....)

MBChB, FRCP, PhD

G.2.5 Professional address :

Medicine for the Elderly

Derby Hospitals NHS Foundation Trust

Uttoxeter Road

Derby

DE22 3NE

UNITED KINGDOM

**G.2. Principal investigators (for multicentre trial; where necessary, use additional forms)**

G.2.1 and G.2.2 and G.2.3  
Name :

Jagdish Sharma

G.2.4 Qualification  
(MD.....)

MBBS, FRCP

G.2.5 Professional address :

Medicine for the Elderly

Sherwood Forest Hospitals NHS Foundation Trust

Mansfield Rd

Sutton-in -Ashfield, Nottinghamshire

NG17 4JL

UNITED KINGDOM

**G.2. Principal investigators (for multicentre trial; where necessary, use additional forms)**

G.2.1 and G.2.2 and G.2.3  
Name : Mohammad Albazzaz

G.2.4 Qualification  
(MD.....) MBChB, FRCP(UK)

G.2.5 Professional address : General Medicine  
  
Barnsley Hospital NHS Foundation Trust  
  
Barnsley Hospital NHS Foundation Trust  
  
Gawber Road, Barnsley  
  
S75 2EP  
  
UNITED KINGDOM

**G.2. Principal investigators (for multicentre trial; where necessary, use additional forms)**

G.2.1 and G.2.2 and G.2.3  
Name :

Khalid Ayes

G.2.4 Qualification  
(MD.....)

MBBS, MRCP(UK), MSc

G.2.5 Professional address :

Stroke Unit

Kettering General Hospital

Kettering General Hospital NHS Trust

Rothwell Rd, Kettering

NN16 8UZ

UNITED KINGDOM

**G.2. Principal investigators (for multicentre trial; where necessary, use additional forms)**

G.2.1 and G.2.2 and G.2.3  
Name :

Melanie Blake

G.2.4 Qualification  
(MD.....)

BMBCh, MRCP

G.2.5 Professional address :

General Medicine

Northampton General Hospital NHS Trust

Cliftonville

Northampton

NN1 5BD

UNITED KINGDOM

**G.2. Principal investigators (for multicentre trial; where necessary, use additional forms)**

G.2.1 and G.2.2 and G.2.3  
Name :

Dinesh Chadha

G.2.4 Qualification  
(MD.....)

MBBS, MD, FRCP

G.2.5 Professional address :

Doncaster and Bassetlaw Hospitals NHS Foundation Trust.

Doncaster and Bassetlaw Hospitals NHS Foundation Trust.

Armthorpe Rd

Doncaster

DN2 5LT

UNITED KINGDOM

**G.2. Principal investigators (for multicentre trial; where necessary, use additional forms)**

G.2.1 and G.2.2 and G.2.3  
Name :

Simon Leach

G.2.4 Qualification  
(MD.....)

MBChB, MRCP

G.2.5 Professional address :

Lincoln County Hospital

United Lincolnshire Hospitals NHS Trust

Greetwell Road

Lincoln

LN2 5QY

UNITED KINGDOM

**G.2. Principal investigators (for multicentre trial; where necessary, use additional forms)**

G.2.1 and G.2.2 and G.2.3  
Name :

David Mangion

G.2.4 Qualification  
(MD.....)

MRCS, LRCP, FRCP

G.2.5 Professional address :

Pilgrim Hospital

United Lincolnshire Hospitals NHS Trust

Sibsey Rd

Boston

PE21 9QS

UNITED KINGDOM

**G.2. Principal investigators (for multicentre trial; where necessary, use additional forms)**

G.2.1 and G.2.2 and G.2.3  
Name :

James Okwera

G.2.4 Qualification  
(MD.....)

MBChB, FRCP

G.2.5 Professional address :

Rotherham General Hospital

The Rotherham NHS Foundation Trust

Moorgate Road,

Oakwood

S60 2UD

UNITED KINGDOM

**G.2. Principal investigators (for multicentre trial; where necessary, use additional forms)**

G.2.1 and G.2.2 and G.2.3  
Name : Sunil Punnoose

G.2.4 Qualification  
(MD.....) FRCP

G.2.5 Professional address : Medicine  
  
Chesterfield Royal Hospital NHS Foundation Trust  
  
Calow, Chesterfield  
  
Derbyshire  
  
S44 5BL  
  
UNITED KINGDOM

**G.2. Principal investigators (for multicentre trial; where necessary, use additional forms)**

G.2.1 and G.2.2 and G.2.3  
Name :

Conran Athulathmudali

G.2.4 Qualification  
(MD.....)

MBBS,FRCP

G.2.5 Professional address :

Eastbourne District General Hospital

East Sussex Hospitals NHS Trust

King's Drive, Eastbourne

East Sussex,

BN21 2UD

UNITED KINGDOM

**G.2. Principal investigators (for multicentre trial; where necessary, use additional forms)**

G.2.1 and G.2.2 and G.2.3  
Name :

Adrian Blight

G.2.4 Qualification  
(MD.....)

MBBS, FRCP

G.2.5 Professional address :

Royal Surrey County Hospital

Royal Surrey County Hospital NHS Trust

Guildford

Surrey

GU2 7XX

UNITED KINGDOM

**G.2. Principal investigators (for multicentre trial; where necessary, use additional forms)**

G.2.1 and G.2.2 and G.2.3  
Name : Gunaratnam Gunathilagan

G.2.4 Qualification  
(MD.....) FRCP

G.2.5 Professional address : Queen Elizabeth The Queen Mother Hospital  
  
East Kent Hospitals University NHS Trust  
  
St Peter's Rd  
  
Margate  
  
CT9 4NA  
  
UNITED KINGDOM

**G.2. Principal investigators (for multicentre trial; where necessary, use additional forms)**

G.2.1 and G.2.2 and G.2.3  
Name :

David Hargroves

G.2.4 Qualification  
(MD.....)

MBBS, MRCP(UK), MSc

G.2.5 Professional address :

Ashford Hospital

Ashford and St. Peter's Hospitals NHS Trust

London Rd

Ashford, Middlesex

TW15 3AA

UNITED KINGDOM

**G.2. Principal investigators (for multicentre trial; where necessary, use additional forms)**

G.2.1 and G.2.2 and G.2.3  
Name :

Hugh Markus

G.2.4 Qualification  
(MD.....)

BMBCH, DM, FRCP

G.2.5 Professional address :

Neurology Dept

St George's Healthcare NHS Trust

Blackshaw Rd

Tooting

SW17 0QT

UNITED KINGDOM

**G.2. Principal investigators (for multicentre trial; where necessary, use additional forms)**

G.2.1 and G.2.2 and G.2.3  
Name :

Keith Mundy

G.2.4 Qualification  
(MD.....)

MBBChir, FRCP

G.2.5 Professional address :

Frimley Park Hospital

Frimley Park Hospital NHS Foundation Trust

Portsmouth Road, Frimley,

Surrey

GU16 7UJ

UNITED KINGDOM

**G.2. Principal investigators (for multicentre trial; where necessary, use additional forms)**

G.2.1 and G.2.2 and G.2.3  
Name :

Mehool Patel

G.2.4 Qualification  
(MD.....)

MBBS

G.2.5 Professional address :

The Lewisham Hospital

The Lewisham Hospital NHS Trust

Lewisham High Street

London

SE13 6LH

UNITED KINGDOM

**G.3. Central technical facilities to be used in the conduct of the trial. Laboratory or other technical facility, in which the measurement or assessment of the main evaluation criteria are centralised (repeat as needed for multiple organisations)**

G.3.1 Organisation Department: Cardiovascular Medicine

Organisation Name: University of Nottingham

G.3.2 Name of contact person : Stanley Heptinstall

G.3.3 Address : Cardiovascular Medicine, QMC

Nottingham

NG7 1DR

UNITED KINGDOM

G.3.4 Telephone number : 01158231013

G.3.5 Duties subcontracted : Primary/ surrogate endpoint test

**G.3. Central technical facilities to be used in the conduct of the trial. Laboratory or other technical facility, in which the measurement or assessment of the main evaluation criteria are centralised (repeat as needed for multiple organisations)**

G.3.1 Organisation Department: Clinical Neuroscience

Organisation Name: St George's University of London

G.3.2 Name of contact person : Hugh Markus

G.3.3 Address : Cranmer Terrace

London

SW17 ORE

UNITED KINGDOM

G.3.4 Telephone number : 02087252735

G.3.5 Duties subcontracted : Primary/ surrogate endpoint test

**G.4. Organisations to whom the sponsor has transferred trial related duties and functions (repeat as needed for multiple organisations)**

G.4.1 Has the sponsor transferred any major or all the sponsor's trial related duties and functions to another organisation or third party ?

yes  no

Repeat as necessary for multiple organisations :

G.4.1.1 Organisation Department: Stroke Medicine

Organisation Name: University of Nottingham

G.4.1.2 Name of contact person : Philip Bath

G.4.1.3 Address : CSB, Nottingham City Hospital

Nottingham

NG5 1PB

UNITED KINGDOM

G.4.1.4 Telephone number : 01158231765

Duties/functions subcontracted :

G.4.1.5 All tasks of the sponsor yes  no

G.4.1.6 Monitoring yes  no

G.4.1.7 Regulatory yes  no

G.4.1.8 Investigator Recruitment yes  no

G.4.1.9 IVRS<sup>26</sup> - treatment randomisation yes  no

G.4.1.10 Data Management yes  no

G.4.1.11 E-data capture yes  no

G.4.1.12 SUSAR reporting yes  no

G.4.1.13 Quality assurance auditing yes  no

G.4.1.14 Statistical analysis yes  no

G.4.1.15 Medical writing yes  no

G.4.1.16 Other duties subcontracted yes  no

G.4.1.16.1 If Yes to Other please specify :

<sup>26</sup> Interactive Voice Response System : commonly used for randomisation of treatment and controlling the shipment of stock of product.

## H. COMPETENT AUTHORITY / ETHICS COMMITTEE IN THE MEMBER STATE CONCERNED BY THIS REQUEST

### H.1 Type of application

If this application is addressed to the Competent Authority, please tick the Ethics Committee box and give information on the Ethics committee concerned. If this application is addressed to the Ethics Committee, please tick the Competent Authority box and give information on the Competent Authority concerned.

**H.1.1 Competent Authority**

**H.1.2 Ethics Committee**

### Information on Competent Authorities / Ethics Committees

H.2.1 Name : Trent MREC

Address : Derwent Shared Services, 6th Floor Laurie House, Colyear St

Derby

DE1 1LJ

UNITED KINGDOM

H.2.2 Date of submission : 2008-08-12

H.3 Authorisation/opinion :  H.3.1 to be requested  H.3.2 pending  H.3.3 given

If given, specify: H.3.3.1 Date of authorisation / opinion:

H.3.3.2 authorisation accepted / opinion favourable:

H.3.3.3 not accepted / not favourable.

If not acceptable / not favourable, give :

H.3.3.3.1 - the reasons

H.3.3.3.2 - the eventual anticipated date of resubmission :

## I. SIGNATURE OF THE APPLICANT IN THE MEMBER STATE

I.1 I hereby confirm that / confirm on behalf of the sponsor (delete which is not applicable) that

- the above information given on this request is correct
- the trial will be conducted according to the protocol, national regulation and the principles of good clinical practice
- It is reasonable for the proposed clinical trial to be undertaken.
- I will submit reports of suspected unexpected serious adverse reactions and safety reports according to applicable guidance.
- I will submit a summary of the final study report to the competent authority and the ethics committee concerned within a maximum 1 year deadline after the end of the study in all countries.

I.3 APPLICANT of the request for the competent authority(as stated in section C1) :

I.3.1 Date : 12 August 2008

I.3.2 Signature <sup>27</sup> 

I.3.3 Print name : P BATH

---

<sup>27</sup> On an application to the Competent Authority only, the applicant to the Competent Authority needs to sign.